---
title: Regulatory Affairs for Biologics, ADCs & CGT | CBS
description: Regulatory strategy, CMC and clinical pharmacology authoring, and FDA/EMA interactions for IND, CTA, BLA and MAA submissions.
image: https://www.crystalbiosolutions.com/hubfs/AI-Generated%20Media/Images/Regulatory%20Affairs%20Lab%20Scientists%20With%20Documents.png
---

![Crystal Bio Solutions logo](https://www.crystalbiosolutions.com/hs-fs/hubfs/Crystal%20Bio%20Solutions%20logo.webp?width=330&height=150&name=Crystal%20Bio%20Solutions%20logo.webp)

- Bioanalysis & Biomarkers 
    - [All Bioanalysis & Biomarker Services](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [PK Assays for Biologics & ADCs](https://www.crystalbiosolutions.com/services/pk-bioanalysis)
    - [NAb & ADA Immunogenicity Assays](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk)
    - [Receptor Occupancy Assays](https://www.crystalbiosolutions.com/services/receptor-occupancy-assays)
- Biologics CMC Analytical 
    - [All Biologics CMC Analytical Services](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Developability Assessment](https://www.crystalbiosolutions.com/services/biologics-developability-assessment)
    - [Extended Characterization by HRMS](https://www.crystalbiosolutions.com/services/biologics-extended-characterization-hrms)
    - [Biotransformation & In Vivo CQA](https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa)
- [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
- Solutions 
    - [ADC Programs](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc)
    - [Regulatory Affairs Support](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)

- [Resources](https://www.crystalbiosolutions.com/news-and-events)
- [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
- [About Us](https://www.crystalbiosolutions.com/about-us)
- [Locations](https://www.crystalbiosolutions.com/locations)
- [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Request a Proposal](https://www.crystalbiosolutions.com/contact-us)

![Regulatory Affairs Lab Scientists With Documents](https://www.crystalbiosolutions.com/hs-fs/hubfs/AI-Generated%20Media/Images/Regulatory%20Affairs%20Lab%20Scientists%20With%20Documents.png?width=960&height=640&name=Regulatory%20Affairs%20Lab%20Scientists%20With%20Documents.png)

# Regulatory Support for All Stages of Development

Crystal Bio Solutions, part of Crystal Group, provides regulatory affairs support through strategic partners with senior regulatory experts in the US, EU and China. Coordinated with our bioanalysis, CMC analytical and clinical pharmacology work, the team designs global regulatory strategies, authors submission documents and supports authority interactions from IND/CTA through BLA/MAA, using ICH-aligned practices and eCTD publishing. The responsible legal entity, laboratory and applicable quality system are defined in each proposal and statement of work.

[![Let's talk](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/146565877/interactive-264126601418.png)](https://www.crystalbiosolutions.com/hs/cta/wi/redirect?encryptedPayload=AVxigLJPzhBEdkLLQAX%2FaqokPQPzVHHO%2B4BNu7snOFVwwcKOqwCu%2FLiihhm9BYImtlQn4mZ7Qe6NoSx90co0dbw7dwe9OsvTznHZZdLsZEWjXorDhKN9oPu1h5ZdG%2F9bHKOrgs9UuazBgI2AoBI3%2BmmQSjQheOaFkyM7%2BzE6VoVMolFlAGwuEbuTsbEQwieHAO7CHrXD93gatTN1yli%2B1QU2qfWqQ9du&webInteractiveContentId=264126601418&portalId=146565877&hsLang=en)

![CBS orange-blue banner-1](https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20orange-blue%20banner-1.png?width=2000&height=21&name=CBS%20orange-blue%20banner-1.png "CBS orange-blue banner-1")

Regulatory Strategy Guidance across development: target product profile and gap assessments, global/bridging plans (FDA/EMA/NMPA), indication and study pathway, comparability for biologics/ADCs, and expedited designations (Fast Track, Breakthrough, RMAT, PRIME) when appropriate. Authoring & Medical Writing Clear, defensible documentation: protocols and IBs, SAPs, CSRs, nonclinical/clinical overviews (CTD Modules 2–5), patient-facing ICFs, briefing packages, and written responses aligned to ICH, GCP, and local guidance. Submission & Approval Submission operations and lifecycle: IND/CTA preparation, eCTD compilation/publishing, QC, query management, variations/supplements, and post-marketing commitments; delivered on schedule and audit-ready.

![Doctor in a white coat with a stethoscope reviews a blue clipboard, pen in hand, with a white pill bottle on the desk.](https://www.crystalbiosolutions.com/hs-fs/hubfs/Physician%20reviewing%20prescription%20notes.webp?width=640&height=480&name=Physician%20reviewing%20prescription%20notes.webp) Relationships With Authorities Working with our strategic regulatory partners, we support structured communication with FDA, EMA and NMPA on behalf of sponsors. The team plans meeting strategy, prepares briefing packages and written responses, manages timelines and minutes, and guides query resolution from pre-IND/Scientific Advice through approval.

**Highlights:**  
• Pre-IND/Scientific Advice strategy and questions  
• Briefing books, slide decks and meeting rehearsals  
• Written responses, minutes and follow-ups  
• Ongoing query management and risk tracking ![Clinician adjusts an IV catheter for a seated patient wearing a headscarf in an infusion clinic.](https://www.crystalbiosolutions.com/hs-fs/hubfs/Clinician%20preparing%20an%20IV%20infusion%20for%20a%20patient.webp?width=640&height=480&name=Clinician%20preparing%20an%20IV%20infusion%20for%20a%20patient.webp) Therapeutic Expertise Through our partners, CBS supports regulatory work for complex programs across biologics, ADCs and CGT, as well as small molecules and 505(b)(2) when needed.

**Modalities and programs:**  
• Monoclonal and bispecific antibodies, fusion proteins, biosimilars  
• ADCs (clinical experience)  
• Radiopharmaceuticals  
• Cell and gene therapy programs  
• Small molecules and 505(b)(2) applications

## Frequently Asked Questions

 

### What is the difference between an IND and a CTA?

An Investigational New Drug application (IND) is submitted to the US FDA before clinical trials begin in the United States. A Clinical Trial Application (CTA) serves a similar purpose in the European Union and other regions. Content overlaps substantially (quality, nonclinical and clinical information), but format, review process and timelines differ by region.

 

### When should a sponsor request a pre-IND meeting with FDA?

A pre-IND meeting is most useful once the nonclinical program and first-in-human design are defined but before studies are locked, so FDA feedback can still shape the plan. Sponsors typically submit the meeting request with specific questions on CMC, nonclinical and clinical topics several months ahead of the planned IND submission.

 

### Which expedited programs are available for innovative therapies?

In the US, eligible programs may receive Fast Track, Breakthrough Therapy, or Regenerative Medicine Advanced Therapy (RMAT) designation, as well as Priority Review and Accelerated Approval. In the EU, PRIME supports medicines addressing unmet medical needs. Eligibility depends on the condition, the available evidence and the development stage.

 

### How is a regulatory submission organized in the Common Technical Document?

The CTD has five modules: Module 1 (regional administrative information), Module 2 (summaries and overviews), Module 3 (quality/CMC), Module 4 (nonclinical study reports) and Module 5 (clinical study reports). Submissions are compiled and published electronically in eCTD format.

 

### What is required to demonstrate comparability after a manufacturing change?

Under ICH Q5E, sponsors compare quality attributes before and after the change using orthogonal analytical methods. If analytical data cannot exclude an impact on safety or efficacy, additional nonclinical or clinical data may be needed. For ADCs, conjugation-related attributes add further complexity.

 

### Can Crystal Bio Solutions support submissions in multiple regions?

Yes. Through our strategic regulatory partners, we support programs with FDA, EMA and NMPA, including regional strategy and bridging, authoring, eCTD publishing, authority meeting preparation and query management, from IND/CTA through BLA/MAA.

 

## Have a Question?

Bring a real problem to our Chief Scientific Officers: one hour, at no cost, with a CDA in place first.

[Request a Free Consultation](https://www.crystalbiosolutions.com/scientific-consultation?hsLang=en)

![Crystal Bio Solutions logo (footer)](https://www.crystalbiosolutions.com/hubfs/Logo_CBS-%E7%AB%96%E7%89%88-%E5%8F%8D%E7%99%BD.png)

- [Our Services](https://www.crystalbiosolutions.com) 
    - [Bioanalysis & Biomarkers](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [Biologics CMC Analytical](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
    - [Regulatory Affairs](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)
- [Information](https://www.crystalbiosolutions.com/news-and-events) 
    - [About Us](https://www.crystalbiosolutions.com/about-us)
    - [Quality & Compliance](https://www.crystalbiosolutions.com/quality-and-compliance)
    - [News & Events](https://www.crystalbiosolutions.com/news-and-events)
    - [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
    - [Scientific Articles](https://www.crystalbiosolutions.com/news-and-events/tag/blog)
    - [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Contact](https://www.crystalbiosolutions.com/contact-us) 
    - [Email Us](mailto:cbs_bd@crystalpharmatech.com)
    - [Contact Form](https://www.crystalbiosolutions.com/contact-us)
    - [Our Locations](https://www.crystalbiosolutions.com/locations)
    - [Crystal Group](https://www.crystalbiosolutions.com/about-us#crystal-group) 
          - [Crystal Pharmatech](https://www.crystalpharmatech.com/)
          - [Crystal NAX](https://www.crystalnax.com/)

<https://www.linkedin.com/company/crystal-bio-solutions/> [Follow us on LinkedIn News, events and openings](https://www.linkedin.com/company/crystal-bio-solutions/)

- [Privacy Policy](https://www.crystalbiosolutions.com/policies/privacy-policy)
- [Terms of Service](https://www.crystalbiosolutions.com/policies/terms-of-service)

Copyright © 2026 Crystal Bio Solutions, Inc. All rights reserved.

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/#organization",
  "@type" : "Organization",
  "alternateName" : "CBS",
  "contactPoint" : [ {
    "@type" : "ContactPoint",
    "contactType" : "sales",
    "email" : "cbs_bd@crystalpharmatech.com",
    "url" : "https://www.crystalbiosolutions.com/contact-us"
  } ],
  "logo" : "https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20VI%20v2/CBS%20Logo.png",
  "name" : "Crystal Bio Solutions",
  "parentOrganization" : {
    "@type" : "Organization",
    "name" : "Crystal Group",
    "url" : "https://www.crystalpharmatech.com/"
  },
  "sameAs" : [ "https://www.linkedin.com/company/crystal-bio-solutions/" ],
  "url" : "https://www.crystalbiosolutions.com/"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/#website",
  "@type" : "WebSite",
  "inLanguage" : "en",
  "name" : "Crystal Bio Solutions",
  "publisher" : {
    "@id" : "https://www.crystalbiosolutions.com/#organization"
  },
  "url" : "https://www.crystalbiosolutions.com/"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt/#webpage",
  "@type" : "WebPage",
  "about" : {
    "@id" : "https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt/#service"
  },
  "breadcrumb" : {
    "@id" : "https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt/#breadcrumb"
  },
  "description" : "Regulatory strategy, CMC and clinical pharmacology authoring, and FDA/EMA interactions for IND, CTA, BLA and MAA submissions.",
  "inLanguage" : "en",
  "isPartOf" : {
    "@id" : "https://www.crystalbiosolutions.com/#website"
  },
  "name" : "Regulatory Affairs for Biologics, ADCs & CGT | CBS",
  "url" : "https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt/#service",
  "@type" : "Service",
  "areaServed" : "Worldwide",
  "description" : "Global regulatory strategy, document authoring, eCTD publishing, and authority interactions with FDA, EMA and NMPA from IND/CTA through BLA/MAA, delivered through Crystal Bio Solutions' strategic regulatory partners.",
  "hasOfferCatalog" : {
    "@type" : "OfferCatalog",
    "itemListElement" : [ {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Regulatory strategy"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Authoring and medical writing"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Submission and approval (eCTD)"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Relationships with authorities"
      }
    } ],
    "name" : "Regulatory Affairs"
  },
  "name" : "Regulatory Affairs",
  "provider" : {
    "@id" : "https://www.crystalbiosolutions.com/#organization"
  },
  "url" : "https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt/#breadcrumb",
  "@type" : "BreadcrumbList",
  "itemListElement" : [ {
    "@type" : "ListItem",
    "item" : "https://www.crystalbiosolutions.com/",
    "name" : "Home",
    "position" : 1
  }, {
    "@type" : "ListItem",
    "item" : "https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt",
    "name" : "Regulatory Affairs",
    "position" : 2
  } ]
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt/#faq",
  "@type" : "FAQPage",
  "mainEntity" : [ {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "An Investigational New Drug application (IND) is submitted to the US FDA before clinical trials begin in the United States. A Clinical Trial Application (CTA) serves a similar purpose in the European Union and other regions. Content overlaps substantially (quality, nonclinical and clinical information), but format, review process and timelines differ by region."
    },
    "name" : "What is the difference between an IND and a CTA?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "A pre-IND meeting is most useful once the nonclinical program and first-in-human design are defined but before studies are locked, so FDA feedback can still shape the plan. Sponsors typically submit the meeting request with specific questions on CMC, nonclinical and clinical topics several months ahead of the planned IND submission."
    },
    "name" : "When should a sponsor request a pre-IND meeting with FDA?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "In the US, eligible programs may receive Fast Track, Breakthrough Therapy, or Regenerative Medicine Advanced Therapy (RMAT) designation, as well as Priority Review and Accelerated Approval. In the EU, PRIME supports medicines addressing unmet medical needs. Eligibility depends on the condition, the available evidence and the development stage."
    },
    "name" : "Which expedited programs are available for innovative therapies?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "The CTD has five modules: Module 1 (regional administrative information), Module 2 (summaries and overviews), Module 3 (quality/CMC), Module 4 (nonclinical study reports) and Module 5 (clinical study reports). Submissions are compiled and published electronically in eCTD format."
    },
    "name" : "How is a regulatory submission organized in the Common Technical Document?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Under ICH Q5E, sponsors compare quality attributes before and after the change using orthogonal analytical methods. If analytical data cannot exclude an impact on safety or efficacy, additional nonclinical or clinical data may be needed. For ADCs, conjugation-related attributes add further complexity."
    },
    "name" : "What is required to demonstrate comparability after a manufacturing change?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Yes. Through our strategic regulatory partners, we support programs with FDA, EMA and NMPA, including regional strategy and bridging, authoring, eCTD publishing, authority meeting preparation and query management, from IND/CTA through BLA/MAA."
    },
    "name" : "Can Crystal Bio Solutions support submissions in multiple regions?"
  } ],
  "url" : "https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt"
}
```